Axsome Therapeutics (AXSM) After Mixed Earnings What Does The Valuation Narrative Say
Axsome Therapeutics (AXSM) is under scrutiny after reporting mixed Q2 2026 earnings, with increased revenue but also wider net losses. Despite a recent pullback, the stock shows strong long-term momentum, and analysts currently value it at $282.51 per share, suggesting it is undervalued compared …